for the NHLBI-Sponsored Dynamic Registry Investigators Background-Percutaneous coronary intervention (PCI) has witnessed rapid technological advancements, resulting in improved safety and effectiveness over time. Little, however, is known about the temporal impact on patient-reported symptoms and quality of life after PCI. Methods and Results-Temporal trends in post-PCI symptoms were analyzed using 8879 consecutive patients enrolled in the National Heart, Lung, and Blood Institute-sponsored Dynamic Registry (wave 1: 1997 [bare metal stents], wave 2: 1999 [uniform use of stents], wave 3: 2001 [brachytherapy], wave 4, 5: 2004, 2006 [drug eluting stents]). Patients undergoing PCI in the recent waves were older and more often reported comorbidities. However, fewer patients across the waves reported post-PCI angina at one year (wave 1 to 5: 24%, 23%, 18%, 20%, 20%; P trend Ͻ0.001). The lower risk of angina in recent waves was explained by patient characteristics including use of antianginal medications at discharge (relative risk [95% CI] for waves 2, 3, 4 versus 1: 1.0 [0.9 to 1.2], 0.9 [0.7 to 1.1], 1.0 [0.8 to 1.3], 0.9 [0.7 to 1.1])
P ercutaneous coronary intervention (PCI) has now been in use for 3 decades, evolving rapidly with new devices and adjunct therapy. The field has also witnessed widening of profile of patients (and lesions) undergoing the procedure but with a concomitant rise in success rates and reduced need for repeat revascularization. 1, 2 Although the 2 main goals of PCI are prolongation of life or improvement in health status, much focus to date has been placed on the former outcome. Indicators of health status have been shown to carry equal or greater importance than traditional risk factors for mortality in CVD. 3 Though favorable impact of PCI on these "soft" end points have been previously documented, 4 -6 information on temporal trends is lacking. Moreover, durability of symptomrelief with PCI is often attributed to subsequent repeat interventions and reliance on antianginal medications. 7, 8 However, given the documented reduction in repeat interventions in more recent times, trends in the need and type of supplemental therapy need evaluation. The National Heart, Lung, and Blood Institute (NHLBI)-sponsored multicenter Dynamic Registry comprises sequential waves of patients undergoing PCI in North America that span from the era of the bare metal stents to that of the drug-eluting stents. As such, these waves mark important advancements in the field and are ideal to evaluate temporal trends in, and predictors of, post-PCI health status in real-world practice.
WHAT IS KNOWN
• In the last 3 decades, the field of percutaneous coronary intervention (PCI) has evolved rapidly with advancements in technology as well as adjunct and secondary pharmacological therapy. • Contemporary PCI practice includes more patients with severe comorbidities, acute coronary syndromes, and multivessel disease, and yet continues to achieve high procedural success rates with significant reductions in the need for repeat revascularization.
WHAT THE STUDY ADDS
• Temporal trends in patient-perceived symptoms following PCI are indicative of a reduction in the risk of postprocedural angina at 1 year of follow-up. • PCI patients today are managed more often with recommended pharmacological therapy (more ␤-blocker use, less reliance on nitrates and calcium channel blockers), and less often require revascularization (repeat PCI or bypass surgery) after the index procedure. • Women, younger patients, those with prior revascularization or other noncardiac comorbidities are more likely to report symptoms at 1 year, thus warranting further investigation into the plausible underlying mechanisms in these subgroups.
Methods
The prospective, multicenter NHLBI-sponsored Dynamic Registry enrolled consecutive patients undergoing PCI in clinical centers in North America. 1, 2 Consecutive enrollment at each center ended once 200 white men and women were enrolled at that site or 1600 white patients were enrolled across all sites. Then, consecutive minority patients were enrolled until approximately 2000 patients had been enrolled across all sites in the prespecified time intervals or "waves" (consecutive enrollment dates: wave 1: July to November 1997, wave 2: February to April 1999, wave 3: October to December 2001, wave 4: February to April 2004, wave 5: February to May 2006). The research coordinators responsible for data collection participated in a training session before the start of each recruitment wave where the standardized forms and manual of operations are reviewed to ensure consistency in data collection practices. All clinical data collection was performed by the center coordinators via chart review for procedural data and telephone interview, mail questionnaires, or during clinic visits for follow-up data using standardized report forms, guided by a manual of operations and definitions. Written informed consent was obtained for contact after discharge. Information on angina and other health status measures were obtained using brief questions based on reliable questionnaires well-suited for telephone-based interviews. 9, 10 At the time of follow-up, patients were asked if they had chest pain or discomfort (anginal symptoms) in the past 6 weeks, and when present, to describe the severity and frequency of the symptoms. Follow-up angina was then classified by the coordinators as stable or unstable by use of the definitions below. Patients were also asked to self-categorize their level of activity at follow-up as sedentary, mild, moderate, or strenuous, and to self-rate both quality of life and their satisfaction with present quality of life on an 11-point scale (higher scores denoted better quality). Data on events (death, hospitalizations for angina, myocardial infarction [MI], bypass surgery [CABG], and repeat PCI) over 1 year were also ascertained during contact and medical records were reviewed whenever possible for patients requiring repeat hospitalization. The study protocol was approved by the Institutional review boards of the coordinating center (University of Pittsburgh) and all the clinical sites involved.
Definitions
Stable angina was defined as pain precipitated by exertion and relieved by rest or sublingual nitroglycerin, with no change in pattern or severity within 6 weeks before intervention (baseline) or in the previous 6 weeks (follow-up). Unstable angina was defined as either pain presenting at rest, or exertional pain of at least Canadian Cardiovascular Society (CCS) class III that began or increased in severity at least one CCS class in the 2 months before intervention or follow-up. Acute MI, in the first 2 waves, was defined by the documented presence of Ն2 of the following criteria: clinical symptoms, enzyme-level elevations, new wall-motion abnormalities, and Ն2 serial ECG tracings showing changes from baseline or serially in ST-T, or new Q waves in Ն2 contiguous leads; for waves 3 and 4, it was based on either biochemical evidence of necrosis or serial ECG changes. Attempted lesions were considered complex if Ն1 of the following features were present: evidence of thrombus, calcified, at bifurcation, chronic total occlusions (as seen in PCI for reasons other than MI), and ostial lesions. 11 Procedural complications considered included embolization, slow flow, side branch occlusion, abrupt closures, and dissections. Angiographic success was classified as either partial (some but not all attempted lesions successfully treated) or total (all attempted lesions successfully treated). Procedural success was defined as achievement of either partial or total angiographic success without death, MI, or emergency CABG. Supplemental therapy following index PCI comprised the following mutually exclusive groups: (1) bypass surgery alone or with PCI, (2) repeat PCI, or (3) pharmacological maintenance therapy only (PMT, Ն1 of ␤-blockers, calcium channel blockers, and long-acting nitrates).
Statistical Methods
Temporal trends in baseline patient characteristics and outcomes at 1 year were assessed using the Cochran-Armitage test for dichotomous variables 12 and the Jonckeheere-Terpstra test for continuous and nominal/ordinal variables. 13 Differences in cumulative events rates (death, MI, death/MI, nonstaged repeat PCI, bypass surgery) over 1 year across the 5 waves were evaluated using the log-rank test. Difference in baseline characteristics between those with and without angina information was assessed using the Wilcoxon test or 2 test as appropriate. Covariates for multivariable models were identified from factors that differed significantly between the waves and also associated with 1 year outcome using stepwise logistic regression models (P entry Յ0.20, P stay Յ0.10). Logistic regression models were also used to generate propensity scores from baseline and clinical characteristics to account for potential bias introduced by missing outcome data. Given the prospective nature of the analyses using data from multiple clinical sites, the relative risk (95% CI) of post-PCI angina in waves 2 to 5 (reference: wave 1) were estimated using generalized linear models specifying the binomial distribution and log link function (PROC GENMOD in SAS), so as to account for intrasite correlation while providing propensity score-weighted risk estimates. All analyses were performed with SAS version 9.1 (SAS Institute Inc).
Results
Compared to 1997 to 98 (wave 1), consecutive patients (nϭ8879) undergoing PCI in the more recent waves were older and more often reported comorbidities (hypertension, diabetes, and severe noncardiac conditions) and prior revascularization (PCI or CABG; Table 1 ). The index PCI, in these patients, more often involved single vessels/lesions with a concurrent increase in overall stent use (67% in wave 1% to 96% in wave 4; 75% drug-eluting stents in wave 4% to 90% in wave 5). Procedural success was achieved more often with fewer complications in the more recent waves ( Table 2) . Although discharge use of recommended medications (aspirin, antiplatelets, ␤-blockers, and lipid-lowering medications) symptoms, both in the overall cohort (24% in wave 1% to 18% in wave 5, P trend ϭϽ0.001) as well as within specific indication subsets (Table 3 ). However, when present, the symptoms were reported to be more frequent in the recent waves (P trend ϭ0.03). QOL scores were significantly lower in symptomatic patients when compared to their asymptomatic counterparts in each wave (mean scores in waves 1 to 5: angina: 5.8, 5.8, 5.9, 6.2, 6.2 P trend ϭ0.004; no angina: 7.1, 7.4, 7.4, 7.4, 7.2 P trend ϭ0.004). On average, QOL scores in the overall cohort were higher in the more recent waves, even after adjustment for age, sex, race, and concomitant comorbidities (history of diabetes, hypercholesterolemia, hypertension, congestive heart failure, severe noncardiovascular diseases). Figure 1 (top panel) shows the propensity score-weighted relative risk estimates (unadjusted and adjusted) of angina at 1 year in the more recent waves when compared to wave 1. Compared to wave 1, the risk of angina is significantly lower in waves 3, 4, and 5, with no significant difference seen in wave 2 (Figure 1, model 1) . Although adjustment for baseline patient characteristics did not alter the pattern (Figure 1 , model 2), further adjustment for the discharge use of longacting nitrates and calcium channel blockers attenuated the difference between the waves (Figure 1, model 3) . Preprocedural factors that were significantly associated with angina at 1 year in the overall cohort include age (age Ͻ65 years more than Ն65 years), gender (women more than men), and history of prior CABG or PCI (Figure 1, bottom  panel) . Although the overall use of stents was associated with a 15% lower risk of post-PCI angina, prescription of long-acting nitrates or calcium channel blockers at discharge was associated with higher odds of symptoms at 1 The percentage of patients reporting medication use at 1 year, when initially discharged on them, increased over time: aspirin (waves 1 to 5: 81% to 87%), ␤-blockers (75% to 78%), angiotensin-converting enzyme inhibitors (59% to 
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64%), and lipid-lowering medications (76% to 78%). Figure 2 shows the temporal trends in the need for post-PCI supplemental therapy, arranged in the following order of aggressiveness (CABG alone or with repeat PCI more than repeat PCI more than only pharmacological maintenance therapy [PMT] of 1 or more of ␤-blockers or calcium channel blockers or nitrates). In the 1997 to 98 wave, approximately three out of four patients reported PMT use with no additional revascularization over a year. The proportion of PMT use increased with concomitant reductions in the need for repeat interventions (repeat PCI or CABG) across the waves. Specifically, within the PMT group, use of ␤-blockers increased whereas that of longacting nitrates and calcium channel blockers decreased over time (Figure 2 , inset box). Interestingly, the adjusted mean QOL scores in the overall cohort differed by the type of supplemental therapy (PMT: 6.5, repeat PCI: 6.0, CABG: 6.4; P: Ͻ0.001).
Discussion
Ever since its use in 1977, 14 PCI as a treatment modality has witnessed rapid technological advancements with a resultant widening in patient and lesion profiles. The effectiveness of the procedure in relieving symptoms and improving health status has been documented extensively but in specific time periods. 5, 6, [7] [8] [9] [10] [11] [12] [13] [14] [15] Temporal trends in routine practice of PCI reflect higher success rates with significantly reduced need for repeat revascularization over time. 2 The related impact on symptoms and quality of life, however, remains largely unknown. Our report provides a time-sensitive documentation of health status at 1 year after PCI in a prospective multicenter registry spanning a decade of clinical practice. Specifically, the risk of postprocedural angina, as perceived by patients, has decreased over time with fewer repeat interventions and reduced reliance on antianginal medications. The NHLBI-sponsored Dynamic Registry was primarily initiated to provide a snapshot of PCI use in routine practice. As such, the Registry marks the uptake of key devices in the specific time periods: wave 1 (advent of bare metal stents), wave 2 (uniform use of bare metal stents), wave 3 (brachytherapy), wave 4 (advent of drug-eluting stents), and wave 5 (established use of drug-eluting stents). 1,2 Development of these devices was principally aimed at reducing the need for repeat interventions, a goal that has indeed been met over time. 2 The lack of apparent mortality benefit, on the other hand, is viewed in light of the sicker profile of treated patients. This being the case, the reported favorable impact on postprocedural angina speaks broadly to the progress in the field. Admittedly, the lack of baseline health status limits the ability to quantify any meaningful change as a result of the procedure. However, the reported trends are independent of the primary reason for index PCI, the closest representation of baseline symptom status in our cohort. These findings are also noteworthy given the increased use of selective revascularization strategies (more baseline disease but fewer attempts on Ն2 lesions) seen over time.
The "era effect," as represented by the recruitment waves, can be considered a complex synergistic interaction of operator training, technology, and secondary management. The observed trends coincide with improved procedural success, reduced need for long-acting nitrates and repeat revascularizations. Coronary revascularization offers a prime opportunity to ensure initiation of evidence-based secondary pharmacological therapy, and as such the observed temporal trends in use of these medications are encouraging. Adherence to risk factor management and specifically to discharge medications have been previously shown to influence symptoms 16 and long-term outcomes. 17, 18 Therefore, the modest (and nonsignificant) effect of discharge use of individual medications (aspirin, ␤blockers, antiplatelets, and lipidlowering drugs) on symptoms at 1 year deserves mention. Interestingly, differences in cumulative event rates in the Lescol Intervention Prevention study, the landmark trial that established benefits of initiating post-PCI statin therapy, became more apparent after 1 year. 19 Even in the more recent Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, the use of optimal medical therapy resulted in narrowing of the significant difference in angina relief seen with PCI with longer followup. 20 Thus, although it must be acknowledged that data on baseline use or risk factor control was not available in our Registry, it is possible that longer follow-up periods are required to appreciate distinct impact of pharmacotherapy on symptoms.
Durability of symptom-relief with PCI, either alone or when compared to CABG, has often been attributed to subsequent repeat interventions and reliance on antianginal medications. 7, 8 The temporal variation in the use of supplemental therapy in our report, therefore, captures the overall impact of PCI evolution on subsequent patient symptoms. In the prestent era, approximately 1 in 4 patients who underwent PCI outside of acute MI setting and were angina-free at 1 year required repeat intervention (6% CABG and 19% repeat PCI). 21 Subsequent analysis of symptomatic patients in the NHLBI-sponsored Dynamic Registry showed lower repeat revascularization rates with an increase in use of maintenance therapy at 1 year. 6 This trend has certainly improved over time with more patients reporting pharmacological therapy in the setting of fewer subsequent repeat interventions. Reliance on antianginal therapy after PCI has often been considered a limitation of the procedure, and to this end the drastic concomitant reduction in the use of long-acting nitrates and calcium channel blockers is encouraging.
The number of PCIs performed in the United States has increased by almost 300% since 1987, and therefore reports of postprocedural symptoms, even if only in 18% to 25% of patients, demands enquiry. This becomes especially crucial given the absence of documented mortality benefit with PCI and symptom relief becomes the primary goal of the procedure. The impact of PCI on health status has been extensively studied, 6, [22] [23] [24] and predictors of post-PCI symptoms identified. 25 We extend these reports to present correlates of postprocedural symptoms after accounting for the evolution in the field. Patient factors associated with post-PCI angina, in models that adjusted for the "waves," included female gender, younger age, severe concomitant noncardiac comorbidities, and history of prior revascularization. These findings are consistent with previous reports 6, 26, 27 and reemphasize the need to explore potential mechanisms. For example, certain subgroups like women are prone to ischemia even in the absence of significant stenoses with endothelial dysfunction and other noncardiac causes as plausible mechanisms. 28 On the other hand, patients with prior and repeat revascularizations may be reflective of subsets with chronic disease burden not amenable/suitable for revascularization per se. Medical decision-making is a complex multifactorial process with interplay of physician discretion, patient preference, and treatment affordability. However, the above findings along with the small but significant increase in procedures performed for reasons other than angina or MI calls into question the appropriateness of PCI use, both from a clinical as well as economic standpoint.
Limitations
Patient-centered outcomes are gaining rapid attention both in the decision-making process as well as for assessment of procedural performance. 29, 30 To this end, it is encouraging to see that the overall prevalence and risk of patient-perceived symptoms following PCI has decreased over time. The enrollment of consecutive patients with no exclusion criteria and the use of standardized data collection procedures across the waves strengthen these comparisons. Nevertheless, our results must be viewed in the context of the limitations inherent to use of a registry database and the potential effect of residual confounding cannot be ruled out. The NHLBIsponsored Dynamic Registry was initiated to primarily provide a snapshot of PCI use as a treatment modality for coronary artery disease, and as such relied on voluntary participation of clinical centers. Majority of the sites, therefore, are medium-to high-volume hospitals and academic centers, thus limiting the generalizability of our findings. The Registry was also designed to allow for maximum data collection with efficient use of limited resources. Patientreported outcomes in our registry, therefore, were captured only at follow up using brief questions leading to limited characterization. Even so, the association of symptoms with poor quality of life ratings supports the validity of our assessment in this cohort. Health status indicators are also influenced by social environment, relationships, personal values, and emotions, 31,32 all details not collected in our registry. Future research, therefore, will focus on evaluating the long-term impact of the available measures, as a means to identifying their prognostic usefulness.
Conclusion
Our report documents favorable temporal trends in the prevalence and risk of post-PCI angina in a large, prospective, multicenter registry of routine clinical practice. Postprocedural management in contemporary practice reflects greater use of recommended pharmacological therapy with fewer subsequent repeat interventions. Specific subgroups, however, continue to be associated with symptoms at one year and warrant closer attention.
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